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ABSTRACT
Circulating cell-free DNA (cfDNA) has been intensively investigated as a diagnostic and prognostic marker for various 
cancers. In recent years, presence of unmethylated insulin cfDNA in the circulation has been correlated with pancreatic 
β-cell death and risk of developing type 1 diabetes. Digital (d)PCR is an increasingly popular method of quantifying insulin 
cfDNA due to its ability to determine absolute copy numbers, and its increased sensitivity when compared to the more 
routinely used quantitative PCR. Multiple platforms have been developed to carry out dPCR. However, not all technolo-
gies perform comparably, thereby necessitating evaluation of each platform. Here, we compare two dPCR platforms: the 
QuantStudio 3D (QS3D, Applied Biosystems) and the QX200 (Bio-Rad), to measure copies of unmethylated/methylated 
insulin plasmids. The QS3D detected greater copy numbers of the plasmids than the QX200 (manual mode), whereas 
QX200 demonstrated minimal replicate variability, increased throughput, ease of use and the potential for automation. 
Overall, the performance of QX200, in our hands, was better suited to measure differentially methylated insulin cfDNA.
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INTRODUCTION
The concept of circulating cell-free DNA (cfDNA) as a biomarker 
is well established in the area of cancer biology [1-3]. It utilizes a less 
invasive method of assessing an individual’s health status using liquid 
biopsy (e.g., blood, plasma, urine) samples. In the progression to type 
1 diabetes (T1D), immune-mediated loss of insulin-producing β-cells 
starts much earlier than the clinical diagnosis of the disease [4]. This 
trend of gradual β-cell death suggests that detection of β-cell-specific 
cfDNA has great potential as a biomarker of T1D progression.
Despite having an identical genome, each cell type within the body 
contains DNA with a unique methylation pattern that reflects upon 
their specific gene expression profile. The insulin gene, including the 
promoter region, is typically unmethylated within the pancreatic β-cells, 
but methylated in almost all other cell types, thereby providing a strong 
rationale to develop assays to quantify methylated and unmethylated 
insulin DNA as a measure of islet β-cell death [5-10]. These studies 
have used different methods including nested PCR, TaqMan multiplex 
PCR, digital PCR (dPCR) and sequencing to measure circulating un-
methylated insulin cfDNA.
dPCR is becoming an increasingly popular method of quantifying 
nucleic acids as it is able to provide absolute quantitation of target 
gene/transcript copies, thereby offering a more sensitive and absolutely 
quantifiable technology than conventional real-time qPCR and other 
existing technologies [11-14]. cfDNA is often present in low levels 
within circulation, making it difficult to detect via other molecular 
methods thus favoring dPCR due to its robust and sensitive nature. It 
is a technological refinement of qPCR that is achieved by splitting the 
clonal amplification into thousands of distinct reactions. By reading 
the fluorescence of each of these reactions as positive (the sequence of 
interest is present) or negative (no sequence of interest), digital PCR 
can apply the Poisson distribution to calculate the absolute copy num-
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ber of the sequence of interest. Various studies have used dPCR as a 
quantitative tool for gene detection in different diseases such as diabetes 
[7], cancer [15], and infectious diseases [16]. Like any other technique, 
multiple platforms including the Droplet Digital™ PCR system (Bio-
Rad), the RainDrop® Digital PCR system (RainDance Technologies) and 
QuantStudio® 3D Digital PCR system (Life Technologies) have been 
developed to utilize it and these must be compared to ensure robust 
reproducibility and ease of use.
Present study evaluates two digital PCR platforms: the QuantStudio® 
3D (QS3D, Applied Biosystems) and the QX200 Droplet Digital™ 
(QX200, Bio-Rad) to measure unmethylated and methylated insulin 
cfDNA. The QS3D uses a finely-crafted chip with 20000, equally sized, 
nanoscale reaction wells to partition the amplification reaction. The 
QX200 system relies on a droplet generator that splits the PCR reaction 
in up to 20000 aqueous droplets within the emulsion oil. The repro-
ducibility of each platform was assessed using mixtures of methylated 
and unmethylated insulin DNA plasmids. This step was essential before 
analyzing the actual samples from individuals with and without T1D.
MATERIALS AND METHODS
Plasmids
Unmethylated (UM) and methylated (M) Ins plasmids [7] were 
amplified by transfecting into MAX Efficiency® DH5α™ Competent 
Cells (Thermo Fisher), and selected by using 50 µg/ml ampicillin. 
Plasmids were purified using the ZymoPURE Plasmid Midi Prep DNA 
Isolation Kit (Zymo Research). Purified plasmids (3.9 kB) were com-
bined to create solutions with varying percentages of each unmethylated 
(UM) and methylated (M) plasmids. The percentages used were 100%, 
99.9%, 99%, 90%, 75%, 50%, 25%, 10% and 0%. Each mixture had 
the remaining volumes made up with the percentage of other plasmid 
(i.e., the 90% UM plasmid solution had 10% M plasmid). Each solution 
had a total final concentration of 0.5 pg/μl. In order to better visualize 
these results, data for four dilutions (99.9:0.1 and 99.0:1.0 for both 
methylated and unmethylated plasmids) were not included in figures.
Digital PCR
Digital PCR was performed as per the method described in the 
article by Fisher et al. [7]. Each plasmid mixture (as described above) 
and a no template control (NTC) were run in triplicate. The digital PCR 
reactions were as follows: 1× QuantStudio 3D Digital PCR Mastermix 
v2 (Applied Biosystems) or 1× ddPCR Supermix for Probes (No dUTP) 
(Bio-Rad), 1× Custom TaqMan SNP assay AH21BH1, 10U EcoR1, 
nuclease-free water and 0.5 pg (1 μl) of the plasmid mix. Total reaction 
volume for the QS3D was 14.5 μl, while total reaction volume for the 
QX200 was 20 μl as per the manufacturer’s recommendations. Detailed 
compositions are presented in Table 1. Partitioning of PCR reaction 
was achieved using manual droplet generation (Bio-Rad) or nanofluidic 
chip loading (Applied Biosystems) as per the respective manufacturer’s 
protocol. Once the reactions were partitioned, they were amplified using 
the following cycling conditions: 95°C for 10 min, 40 cycles (94°C for 
30 s, 57.5°C for 1 min), 98°C for 10 min, 12°C hold. The ramp rate for 
thermocyling condition was set to 2°C/s for all steps. After PCR, each 
nanofluidic chip was placed face-up and read separately (one at a time) 
in the QS3D. Each chip analysis took < 30 s. The QS3D captured the 
ROX, FAM, and VIC fluorescence of each well on the chip, with ROX 
used as a passive dye to ensure sample loading. On the other hand, the 
PCR amplified droplets from QX200 generator were read from one 
well at a time by streamlining them into a single file that passes through 
a two-color optical detection system on the QX200 Droplet Reader.
Statistics
Plasmid dilutions were assayed in triplicate for each of the dPCR 
experiments performed on the QS3D and QX200 platforms. Pearson 
correlation coefficients and two-tailed P values were calculated using 
GraphPad Prism 7 software. P value of < 0.05 was considered significant 
in the group-wise comparisons.
Table 1. Composition of mastermix for digital PCR reactions.
    QS3D (µl/reaction) QX200 (µl/reaction)
QuantStudio 3D digital 
PCR Mastermix v2 (2 ×)
7.25 -
ddPCR Supermix for 
Probes (No dUTP) (2 ×)
- 10
Custom TaqMan SNP 
assay AH21BH1 (20 ×)
0.725 1
20 U/µl EcoR1 0.5 0.5
Nuclease free water 5.025 7.5




Table 1 presents volumes of each component to be added in the mastermix 
for digital PCR reaction on each platform. Final volumes are calculated based 
on the number of reactions to be run and always calculating for 5% extra 
reactions to account for pipetting errors.
RESULTS
Overview of digital PCR platforms
Figure S1 presents an overview of the two dPCR technologies 
(QS3D and QX200) that are compared here.
QS3D system uses a chip that has 20000 wells etched on a silicon 
substrate with each well of a maximum width of 60 µM (S1A), while 
the QX200 generates up to the same number of droplets by mixing the 
PCR reaction in oil (S1B) either manually or using an automated droplet 
generator. After partitioning the PCR mix, end-stage PCR is performed 
and then the PCR product is analyzed for presence of different fluores-
cent probes as described in the methods. Once the dPCR reactions have 
been completed, a threshold must be placed on both the FAM and VIC 
fluorescence to determine partitions that separate amplified products that 
are negative for both probes, positive for a single probe, or those that 
are positive for both probes. Figure S1C and S1D show representative 
plots of these thresholds on both platforms. The identification of these 
populations varies on the QS3D platform, resulting in an overlay with 
no discernible populations (Fig. S1C), which makes it difficult to set 
up the same threshold for multiple samples using the QS3D platform. 
On the other hand, the QX200 consistently separates droplets into four 
distinct populations (Fig. S1D).
J Biol Methods  | 2019 | Vol. 6(2) | e113 3
POL Scientific
benchmark
Accuracy of the data on both dPCR platforms
The plasmid mixtures were analyzed on both dPCR platforms, and 
their absolute copy numbers were determined (Fig. 1A and 1B).
None of the platforms were able to detect insulin cfDNA plasmids 
with 100% efficiency. The QS3D platform, however, demonstrated a 
1.8-fold higher insulin cfDNA copy number (Fig. 1A) than that detected 
on the QX200 platform (Fig. 1B). The mixing ratios of the unmethyl-
ated and methylated insulin plasmids were correctly reflected on both 
the platforms. We then plotted expected and observed percentages of 
mixtures for both the plasmids (Fig. 1C and 1D). Although data ob-
tained from both platforms show a preferential expression of methylated 
insulin plasmid in all combinations and on both the platforms, both the 
unmethylated and methylated insulin plasmids demonstrated a very 
good correlation with Pearson r = 0.9958 and P < 0.0001 on QS3D 
and Pearson r = 0.9954 and P < 0.0001 on QX200 between expected 
and observed ratios for the two plasmids.
Figure 1. Quantification of unmethylated and methylated insulin DNA. Mixtures containing different proportions of unmethylated and methylated 
insulin plasmids (presented on X axis) were analyzed on the QS3D and QX200 dPCR platforms. Absolute copy numbers (copies/µl) generated from these 
different combinations on QS3D (A) and QX200 (B) platforms are presented as mean + SD. We then plotted expected versus observed percentages of 
unmethylated and methylated insulin plasmid mixtures on QS3D (C) and QX200 (D) platforms. Each plasmid mixture was run in triplicate. Dotted lines 
are expected percentages.
Reproducibility of measurements on both the dPCR 
platforms
Both the platforms are designed to partition the PCR reaction into 
around 20000 individual reactions for PCR. During normal operation, 
however, neither of these platforms utilized the maximum 20000 par-
titions. Rather, the QS3D employed 17300 ± 624.3 (mean ± SD) wells 
and the QX200 generated 16524 ± 1863 (mean ± SD) usable droplets 
(Fig. 2A).
Whilst both platforms had enough partitions to estimate absolute 
copy numbers, the QS3D demonstrated more consistent partitioning. 
When the coefficients of variation (CVs) were determined for multiple 
measurements of both unmethylated and methylated insulin plasmids, 
we observed that QS3D demonstrated a higher level of variability for 
both the plasmids with significantly higher assay CVs than the QX200 
platform (Fig. 2B). Finally, when NTCs were analyzed on the dPCR 
platforms, the QS3D detected DNA copies more frequently than the 
QX200 (Fig. 2C).
DISCUSSION
Digital PCR offers a major advantage over other PCR technologies 
by enabling absolute quantitation of transcript copy numbers. Although 
a favored method of quantitating low levels of circulating cfDNA, the 
choice of technology can heavily influence the generation and reproduc-
ibility of such data [17]. We therefore directly compared two currently 
available dPCR platforms; the QS3D and the QX200.
We find that the absolute copy number values are always higher on 
the QS3D platform (Fig. 1A) as compared to QX200 (Fig. 1B). None 
of the platforms could detect the actual plasmid copy numbers. QS3D 
was seen to measure 1.8-fold more copies than the QX200 platform, 
although it also presented with 3- to 6-fold higher copy numbers in the 
NTC reactions (Fig. 2C). Our analysis identified QX200 dPCR system 
offering higher reproducibility (Fig. 2B).
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Figure 2. Accuracy and reproducibility for manual processing workflows across the two platforms. Number of partitions created on both platforms. 
Scatterplot showing the number of wells (QS3D, blue) or droplets (QX200, green) utilized for the calculation of absolute DNA copy numbers. Data were 
generated from N = 36 per group and presented as mean ± SEM (A). CVs were calculated for each dPCR platform and their distribution for unmethylated 
and methylated assays is shown (B). Data on QS3D (blue) and QX200 (green) platforms are compared as mean ± SEM. NTC was run in triplicate on 
the QS3D (blue) and QX200 (green) platforms and absolute copies are presented in (C) with solid line at mean. ****P < 0.0001.
Table 2. Comparative analysis of two digital PCR platforms.
    QS3D QX200
Min. samples/run 1 8
Samples/8 h (average/max) 24/48 96/192
Detection range (copies/µl) 200–2000 0.25–5000
Supported dye(s) FAM, VIC and ROX* FAM, HEX (or VIC), EvaGreen (or SYBR green)
Time to load one sample (min) 5 1
Time to read one sample (min) 0.5 1.5–2
Ease of loading ++ +++
Ease of analysis ++ +++
Possibility of automation No Yes
Possibility of aerosolic cross-contamination Low High
Cost per sample $$$ $$
Table 2 presents a comparison between QS3D and QX200 platforms in regards to different parameters such as number of samples, loading time, ease 
of handling and ease of analysis. The number of “+” or “$” signs indicate the process being easier (more +s) or more expensive (more $s) than the other. 
*Serve as a reference detection only.
Several other parameters were also compared between the two dPCR 
platforms (Table 2).
Theoretically one sample can be run at a time on QS3D. However, 
the included reagents necessitate multiples of four samples to be pro-
cessed on the QS3D, so as to avoid reagent wastage and achieve cost 
efficiency. It may not be necessary to run positive/negative controls 
every time on QS3D, as each sample is loaded and analyzed separately; 
however, it is always better to include controls to ensure assay validity 
and appropriate separation of populations. QX200 needs at least eight 
samples per run and there should be a positive and negative control 
per run to determine the threshold. The loading of the QS3D chip takes 
longer time as compared to the QX200 platform; however, QS3D chip 
is read in 30 s, whereas the whole 96 well plate on a droplet reader is 
completed in just over two hours (> 1 min per sample). QS3D being a 
closed system has minimal chances of aerosolic contamination, which 
is more likely on QX200 platform. The QX200 is a high throughput 
platform designed for parallel processing of up to 96 samples at a time, 
whilst the QS3D platform has been designed for low sample throughput 
workflows. The throughput of QX200 platform can be further expand-
ed utilizing an automated droplet generator, which not only improves 
droplet numbers but also the assay reproducibility. This is also one 
of the major reasons for QX200 as a preferred platform to undertake 
cfDNA quantitation, particularly in large clinical studies.
There have been previous studies where different platforms are 
compared for cfDNA quantification [18-21]. Four different digital PCR 
platforms (BioMark, QX100, QuantStudio 12k and RainDrop) were 
evaluated for accuracy and measurement uncertainty for known copies of 
a plasmid DNA [18]. It was reported that all the four platforms perform 
equally well in terms of reporting the plasmid concentration within the 
expected range. This report however does not have any evaluation of 
the QS3D platform. Later in another report, QS3D and QX100 were 
compared to observe that QX100 was better in terms of accuracy and 
efficiency with less measurement bias than QS3D [20]. Unlike this 
report, we find that the measurement bias between the expected values 
and observed values for unmethylated and methylated insulin plasmids 
was similar on both QX200 and QS3D platforms. There is one other 
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comparison evaluating only QS3D and QX200 for detecting donor 
cfDNA in acute kidney transplant recipients [21]. This study reported 
QX200 to be better in terms of accuracy and sensitivity for detecting 
donor cfDNA in urine samples of kidney transplant recipients.
Our analysis represents the only comparative study for insulin 
cfDNA measurement using dPCR platforms. This is an important area 
of research wherein the copy number of insulin cfDNA can be used to 
predict the progression to T1D, to assess treatment efficacies of drugs 
that are aimed to retard the death of insulin-producing cells and to esti-
mate the success of islet transplant procedures by assessing the death of 
insulin-producing cells in T1D individuals transplanted with cadaveric 
donor islets. Since different dPCR systems can provide varying esti-
mates, a direct comparison of the two systems becomes necessary. One 
of the limitations is that the current study did not involve comparison 
with other available systems offering absolute quantitation of gene 
transcripts/DNA. However, the QS3D and QX200 are two of the most 
popular systems available to the scientific community and our study 
presents the comparative analysis for researchers aiming to use digital 
PCR platforms for diabetes research. As discussed above, each of the 
two platforms have their own strengths and limitations, which we hope 
would be useful for individual researchers to select for their own study.
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